STAT3抑制对实验性小鼠干眼的治疗作用
研究探讨靶向STAT3激活对小鼠干眼眼表损伤的治疗作用,采用BAC处理、泪腺切除和睑板腺功能障碍三种干眼模型。结果显示三种模型角膜和结膜上皮核内p-STAT3升高,局部应用STAT3抑制剂S3I-201改善BAC诱导干眼小鼠的角膜上皮屏障功能、增加泪液分泌和结膜杯状细胞密度,并降低MMP-3/9、抑制凋亡、减少IL-1β、IL-6、IL-17A和IFN-γ。与托法替尼和鲁索替尼相比,S3I-201在改善泪液分泌和泪腺炎症因子表达方面更优。
要点
- 三种干眼模型角膜和结膜上皮核内p-STAT3水平均升高。
- 局部应用S3I-201改善BAC诱导干眼小鼠的角膜上皮屏障功能、泪液分泌和结膜杯状细胞密度。
- 与托法替尼和鲁索替尼相比,S3I-201在改善泪液分泌和泪腺炎症因子表达方面更优。
核心结论
- 升高的STAT3激活参与干眼发病机制,靶向STAT3可有效减轻BAC诱导的眼表损伤。
研究设计与样本
- 使用BAC处理、泪腺切除和睑板腺功能障碍的成年Balb/C和C57BL/6小鼠作为干眼模型。
- 采用免疫荧光染色和Western blotting检测p-STAT3水平。
- 通过局部应用STAT3抑制剂S3I-201进行STAT3抑制。
主要发现
- 三种干眼模型角膜和结膜上皮中检测到核内p-STAT3水平升高。
- 局部应用S3I-201改善BAC诱导干眼小鼠的角膜上皮屏障功能,增加泪液分泌和结膜杯状细胞密度。
- S3I-201降低MMP-3/9表达,抑制角膜和结膜上皮细胞凋亡,并降低IL-1β、IL-6、IL-17A和IFN-γ水平。
- 与托法替尼和鲁索替尼相比,S3I-201在改善泪液分泌和泪腺炎症因子表达方面表现更优。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the therapeutic effects of targeting signal transducer and activator of transcription-3 (STAT3) activation on the ocular surface damage of dry eye in mice. METHODS: Adult Balb/C and C57BL/6 mice with benzalkonium chloride (BAC) treatment, lacrimal gland excision, and meibomian gland dysfunction were used as dry eye models. The levels of phosphorylated STAT3 (p-STAT3) were detected with immunofluorescence staining and Western blotting. STAT3 inhibition was performed by topical application of STAT3 inhibitor S3I-201. Corneal epithelial barrier function, tear production, and conjunctival goblet cell density were quantified with fluorescein sodium staining, phenol red cotton test, and histochemical staining. The expressions of matrix metalloproteinase (MMP)-3/9, TUNEL, and inflammation cytokines were assessed with immunofluorescence staining, qPCR, and ELISA assays. The therapeutic effect of S3I-201 was further compared with the Janus kinase inhibitor tofacitinib and ruxolitinib. RESULTS: Elevated levels of nuclear p-STAT3 were detected in the corneal and conjunctival epithelium of three dry eye models. Topical application of S3I-201 improved corneal epithelial barrier function, increased tear production and conjunctival goblet cell density in BAC-induced dry eye mice. Moreover, S3I-201 decreased the expression of MMP-3/9, suppressed the apoptosis of corneal and conjunctival epithelial cells, and reduced the levels of IL-1β, IL-6, IL-17A, and IFN-γ. Compared with tofacitinib and ruxolitinib, the STAT3 inhibitor S3I-201 showed superior improvement of tear production and inflammatory cytokine expression in lacrimal gland. CONCLUSIONS: Elevated STAT3 activation is involved in the pathogenesis of dry eye, while targeting STAT3 effectively alleviates BAC-induced ocular surface damage.
引用
- Qu M, Qi X, Wang Q, et al. Therapeutic Effects of STAT3 Inhibition on Experimental Murine Dry Eye. Invest Ophthalmol Vis Sci. 2019. PMID: 31503282. doi:10.1167/iovs.19-26928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。